Preparation of PLGA Microspheres Loaded with Niclosamide Via Microfluidic Technology and Their Inhibition of Caco-2 Cell Activity

Overview

Journal Front Chem

Specialty Chemistry

Date 2023 Oct 2

PMID 37780982

Authors

Yulei Tai

Menglun Tian

Yu Chen

Peijun You

Xiaojun Song

Bangting Xu

Cidong Duan

Dazhi Jin

Affiliations

Soon will be listed here.

Abstract

Niclosamide (NIC) is a multifunctional drug that regulates various signaling pathways and biological processes. It is widely used for the treatment of cancer, viral infections, and metabolic disorders. However, its low water solubility limits its efficacy. In this study, poly(lactic-co-glycolic acid) (PLGA) and hyaluronic acid (HA), which exhibit good biocompatibility, biodegradability, and non-immunogenicity, were conjugated with niclosamide to prepare PLGA-HA-niclosamide polymeric nanoparticles (NIC@PLGA-HA) using microfluidic technology. The obtained microspheres had a uniform size distribution, with an average mean size of 442.0 ± 18.8 nm and zeta potential of -25.4 ± 0.41 mV, indicating their stable dispersion in water. The drug-loading efficiency was 8.70%. The drug-loaded microspheres showed sustained release behavior at pH 7.4 and 5.0, but not at pH 2.0, and the drug release kinetics were described by a quasi-first-order kinetic equation. The effect of the drug-loaded microspheres on the proliferation of Caco-2 cells was detected using the MTT assay. Hydrophilic HA-modified NIC@PLGA-HA microspheres prepared via microfluidic technology increased the cellular uptake by Caco-2 cells. Compared to the same concentration of NIC, the NIC@PLGA-HA microspheres demonstrated a stronger inhibitory effect on Caco-2 cells owing to the combined effect of PLGA, HA, and NIC. Therefore, the pH-responsive NIC@PLGA-HA microspheres synthesized using microfluid technology increased the solubility of NIC and improved its biological activity, thus contributing to the demand for intestinal drug carriers.

Citing Articles

Polyesters and Polyester Nano- and Microcarriers for Drug Delivery.

Slomkowski S, Basinska T, Gadzinowski M, Mickiewicz D Polymers (Basel). 2024; 16(17).

PMID: 39274136 PMC: 11397835. DOI: 10.3390/polym16172503.

References

Vlachopoulos A, Karlioti G, Balla E, Daniilidis V, Kalamas T, Stefanidou M . Poly(Lactic Acid)-Based Microparticles for Drug Delivery Applications: An Overview of Recent Advances. Pharmaceutics. 2022; 14(2). PMC: 8877458. DOI: 10.3390/pharmaceutics14020359. View

Lee R, Choi Y, Jeong M, Park Y, Motoyama K, Kim M . Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer. Bioconjug Chem. 2020; 31(3):923-932. DOI: 10.1021/acs.bioconjchem.0c00048. View

Tavakoli H, Mohammadi S, Li X, Fu G, Li X . Microfluidic platforms integrated with nano-sensors for point-of-care bioanalysis. Trends Analyt Chem. 2023; 157. PMC: 10621318. DOI: 10.1016/j.trac.2022.116806. View

Huang L, Zhang J, Deng Y, Wang H, Zhao P, Zhao G . Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer. Genes Dis. 2023; 10(4):1687-1701. PMC: 10311098. DOI: 10.1016/j.gendis.2022.12.005. View

Rezvantalab S, Drude N, Moraveji M, Guvener N, Koons E, Shi Y . PLGA-Based Nanoparticles in Cancer Treatment. Front Pharmacol. 2018; 9:1260. PMC: 6224484. DOI: 10.3389/fphar.2018.01260. View

Shen X, Li T, Xie X, Feng Y, Chen Z, Yang H . PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications. Front Bioeng Biotechnol. 2020; 8:381. PMC: 7214837. DOI: 10.3389/fbioe.2020.00381. View

Lu X, Miao L, Gao W, Chen Z, McHugh K, Sun Y . Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. Sci Transl Med. 2020; 12(556). PMC: 9019818. DOI: 10.1126/scitranslmed.aaz6606. View

Drozdzal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybycinski J . An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat. 2022; 59:100794. PMC: 8654464. DOI: 10.1016/j.drup.2021.100794. View

McConnell E, Short M, Basit A . An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J Control Release. 2008; 130(2):154-60. DOI: 10.1016/j.jconrel.2008.05.022. View

10.

Pacios O, Blasco L, Bleriot I, Fernandez-Garcia L, Gonzalez Bardanca M, Ambroa A . Strategies to Combat Multidrug-Resistant and Persistent Infectious Diseases. Antibiotics (Basel). 2020; 9(2). PMC: 7168131. DOI: 10.3390/antibiotics9020065. View

11.

Mohammadinejad S, Jafari-Gharabaghlou D, Zarghami N . Development of PEGylated PLGA Nanoparticles Co-Loaded with Bioactive Compounds: Potential Anticancer Effect on Breast Cancer Cell Lines. Asian Pac J Cancer Prev. 2022; 23(12):4063-4072. PMC: 9971482. DOI: 10.31557/APJCP.2022.23.12.4063. View

12.

Singh S, Weiss A, Goodman J, Fisk M, Kulkarni S, Lu I . Niclosamide-A promising treatment for COVID-19. Br J Pharmacol. 2022; 179(13):3250-3267. PMC: 9111792. DOI: 10.1111/bph.15843. View

13.

Xu J, Shi P, Li H, Zhou J . Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020; 6(5):909-915. PMC: 7098069. DOI: 10.1021/acsinfecdis.0c00052. View

14.

Li Z, Xu J, Lang Y, Fan X, Kuo L, DBrant L . JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both and . ACS Infect Dis. 2020; 6(10):2616-2628. PMC: 7559020. DOI: 10.1021/acsinfecdis.0c00217. View

15.

Jeon S, Ko M, Lee J, Choi I, Byun S, Park S . Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob Agents Chemother. 2020; 64(7). PMC: 7318052. DOI: 10.1128/AAC.00819-20. View

16.

Weng X, Maxwell-Warburton S, Hasib A, Ma L, Kang L . The membrane receptor CD44: novel insights into metabolism. Trends Endocrinol Metab. 2022; 33(5):318-332. DOI: 10.1016/j.tem.2022.02.002. View

17.

Xu Y, Shrestha N, Preat V, Beloqui A . Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. J Control Release. 2020; 322:486-508. DOI: 10.1016/j.jconrel.2020.04.006. View

18.

Kaushal J, Bhatia R, Kanchan R, Raut P, Mallapragada S, Ly Q . Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. Cancers (Basel). 2021; 13(13). PMC: 8269055. DOI: 10.3390/cancers13133105. View

19.

Feltrin F, Agner T, Sayer C, Lona L . Curcumin encapsulation in functional PLGA nanoparticles: A promising strategy for cancer therapies. Adv Colloid Interface Sci. 2021; 300:102582. DOI: 10.1016/j.cis.2021.102582. View

20.

Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D . Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature. 2021; 594(7861):88-93. PMC: 7611055. DOI: 10.1038/s41586-021-03491-6. View